On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Aims at Future of Cannabinoid Compound Treatment

  • Specializing in novel cannabinoid drug therapies, InMed Pharmaceuticals is well-poised for cannabinoid research and development of new treatments
  • Glaucoma and skin disease pharmaceuticals now in development have an estimated $7.6 billion potential market
  • InMed Pharmaceutical’s chief medical officer helped $3 billion GW Pharmaceuticals develop one of the first cannabis-based drugs

With its proprietary bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is well-positioned to target the future of cannabinoid pharmaceutical compounds.

InMed is a pre-clinical stage biopharmaceutical company specializing in the development of novel therapies through research and development of the 90+ individual cannabinoid compounds which occur naturally in cannabis.

InMed can rapidly analyze and identify novel cannabinoids to find new drug candidates with the highest therapeutic benefit and fewest adverse effects. The company’s unique research approach using proprietary bioinformatics tools expedites the identification of bioactive compounds with the potential to treat specific diseases, while its comprehensive pharmaceutical and cannabinoid structures database allow InMed to identify active cannabinoids that will act on genes and proteins.

Two major medications are in development by InMed Pharmaceuticals: a glaucoma treatment and a drug therapy for epidermolysis bullosa (EB). The two markets combined have an estimated value of $7.6 billion. Clinical trials for both candidates are expected to start in 2018.

In June, InMed Pharmaceuticals announced an agreement with Pharmaseed Ltd. to develop the final formulation for INM-750, a treatment in development as a therapy for EB and other dermatological and wound applications.

Epidermolysis bullosa comprises a group of inherited connective tissue diseases which typically affect the skin, causing it to become extremely fragile and prone to blistering and tearing. The disease can also affect bodily systems and internal organs. There is currently no approved treatment for EB. InMed’s topical formulation includes multiple cannabinoids to target keratin modulation, as well as inflammation, healing, skin regeneration, itching, and pain.

A second pharmaceutical in InMed’s pipeline, INM-085, treats glaucoma, an eye disorder which increases pressure in the eye, damages the optic nerve and is one of the leading causes of blindness in the developed world. The glaucoma medication could become the first-ever treatment for the disease that is multi-target and uses multiple cannabinoids for maximum effectiveness.

InMed Pharmaceuticals’ impressive management team includes Chief Medical Officer Dr. Ado Muhammed, a former associate medical director for GW Pharmaceuticals. Muhammed was instrumental in leading GW Pharmaceuticals (NASDAQ: GWPH) through development and approval of one of the world’s first cannabis-based drugs, taking the company’s shares from less than $9 in 2013 to $100 today and building a market value of more than $2.5 billion.

InMed Pharmaceuticals president and CEO Eric Adams is a seasoned biopharmaceutical executive with over 25 years’ experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Adams previously served as CEO at enGene Inc. and held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany).

InMed’s Chief Scientific Officer Dr. Sazzad Hossain has more than 20 years of academic and industrial experience in new drug discovery and natural health product development. Hossain held key roles at the Biotechnology Research Institute of National Research Council Canada and Xenon Pharmaceuticals. CFO Jeff Charpentier is a 25-year veteran of the biopharmaceutical industry and has served at several public and private companies in the pharmaceutical and technology sectors.

With lots of opportunity, a share price of less than 30 cents and a market cap of about $34 million, InMed looks like a good opportunity to profit from what may become the next success story in the ongoing quest to cure and mitigate disease with cannabinoid-based therapeutics.

For more information, visit the company’s website at www.InMedPharma.com

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217